Summary & Overview
HCPCS Level II J1120: Injection, Acetazolamide Sodium, up to 500 mg
HCPCS Level II code J1120 denotes an injection of acetazolamide sodium, up to 500 mg, a parenteral carbonic anhydrase inhibitor used when injectable therapy is indicated. This national-level overview explains the clinical context for use, common sites where the service is provided, and why accurate coding matters for clinical documentation and payer adjudication. The code is relevant across hospital outpatient departments, physician offices, and infusion clinics where injectable medications are administered.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise synthesis of the code’s clinical purpose, typical settings of service, and the payer landscape covered. The publication also outlines typical billing considerations, common modifiers used with HCPCS Level II drug codes, and the types of benchmarks and policy updates that affect coverage and reimbursement. Where input data is absent, such as associated taxonomies, ICD-10 diagnoses, or related codes, the summary notes that specific details are not available in the input.
This briefing equips coding professionals, revenue cycle staff, and policy analysts with the essential facts about J1120 to support accurate claims submission, payer communication, and operational planning at a national level.
Billing Code Overview
HCPCS Level II code J1120 represents injection, acetazolamide sodium, up to 500 mg. This code describes a parenteral administration of acetazolamide sodium, a diuretic and carbonic anhydrase inhibitor commonly used for conditions that may include elevated intraocular pressure, certain types of seizure disorders, and fluid retention when oral administration is not feasible.
Service Type: Injection / Parenteral Drug Administration
Typical Site of Service: Outpatient facility, hospital outpatient department, clinic, or physician office where injectable medications are administered. If an inpatient setting or other site is involved, that information is not provided in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with elevated intraocular pressure from acute glaucoma or neurologic conditions causing intracranial hypertension who presents to an outpatient infusion clinic, emergency department, or ophthalmology clinic. The clinician prescribes J1120 (injection, acetazolamide sodium, up to 500 mg) when rapid systemic carbonic anhydrase inhibition is required to reduce aqueous humor production or lower cerebrospinal fluid production. The workflow commonly includes assessment of vital signs and electrolytes, verification of allergy history and current medications (including sulfonamide sensitivity), informed consent, preparation of the injectable formulation by pharmacy or trained nursing staff, administration via intravenous push or slow IV infusion per facility protocol, post‑administration monitoring for hypotension, paresthesia, or metabolic acidosis, and documentation of dose, lot number, route, and patient response. Typical sites of service are outpatient infusion centers, emergency departments, ambulatory surgical centers when used perioperatively, and inpatient hospital wards for acute management.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | When administration required substantially greater resources or time than usual (rare for this injection). |